Keyword: Shanghai Fosun Pharmaceutical Group
Biogen and Bayer deal with coronavirus rule-breakers in China. AbbVie's Kaletra fails COVID-19 study. Fosun licenses BioNTech's coronavirus vaccine.
Hanmi loses Janssen obesity pact, while Yuhan signs NASH deal with Boehringer. GSK sells a Chinese site to Fosun as it opens facilities in Singapore.
Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Fosun Pharma.
Roche, Daiichi and AZ nab global first nods from Japan; Celgene hands back PD-1 to BeiGene; China offers incentive to generic makers.
As Bayer management predicted, it seems as though the German conglomerate’s for-sale animal health business has indeed attracted high interest.
Daiichi rejigs management; China approves its first biosimilar; Sinovac uses a poison pill to fend off an investor takeover.
Chinese authorities have approved Fosun subsidiary Henlius' Rituxan copycat, the country's first biosimilar.
The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.
Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.
In probably a new drug scandal from China, self-proclaimed employees alleged that a Fosun unit faked production and testing records.